Market capitalization | $1.83b |
Enterprise Value | $1.40b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 17.61 |
P/S ratio (TTM) P/S ratio | 23.06 |
P/B ratio (TTM) P/B ratio | 2.58 |
Sales growth (TTM) Sales growth | 70.16% |
Turnover (TTM) Turnover | $79.41m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
16 Analysts have issued a Kymera Therapeutics Inc forecast:
16 Analysts have issued a Kymera Therapeutics Inc forecast:
Mar '24 |
+/-
%
|
||
Turnover | 79 79 |
70%
70%
|
|
Gross income | 75 75 |
73%
73%
|
|
EBITDA | -169 -169 |
2%
2%
|
EBIT (operating result) EBIT | -173 -173 |
2%
2%
|
Net profit | -155 -155 |
3%
3%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.
Head office | United States |
CEO | Nello Mainolfi |
Employees | 187 |
Founded | 2015 |
Website | www.kymeratx.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.